Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

2011 issue of the Journal of Biological Chemistry.
  • Expanded its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include the fields of addiction and compulsive disorders. Currently, Omeros is advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse and The Michael J. Fox Foundation.
  • Announced the identification of compounds that interact selectively with two orphan GPCRs linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now publicly announced that it has successfully unlocked five orphan GPCRs for drug development.
  • Reported positive results from the Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.  In this 221-patient study, subjects treated with OMS302 demonstrated statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure, and OMS302 significantly decreased (p=0.0418) pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). The product candidate was safe and well tolerated in this study.
  • Announced that OMS103HP failed to meet prespecified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery. The data were confounded, and Omeros could not determine whether a drug effect was present in these trials.

  • About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the cen
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... LOUIS , Aug. 19, 2014  Sequence, Inc., an ... for pharmaceutical, biotech and medical device manufacturers is opening a ... St. Louis , as a result of demand ... new location, which opened this month, allows Sequence to better ... Establishing a St. Louis office provides ...
    (Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
    (Date:8/19/2014)... , August 19, 2014 According ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and ... Growth, Trends and Forecast, 2014 - 2020", the global ... million in 2013 and is expected to grow at ... reach an estimated value of USD 295.5 million in ...
    Breaking Medicine Technology:Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
    ... BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... biopharmaceutical products in China, announced today the positive top-line ... proprietary inactivated vaccine against human enterovirus 71 (EV71), which ... Phase II results for the EV71 vaccine showed a ...
    ... HARBIN, China, Nov. 9, 2011 /PRNewswire-Asia/ -- China Sky One ... CSKI ), a leading fully integrated pharmaceutical company producing ... announced financial results for the third quarter of 2011. ... Financial Highlights , Total revenues decreased 26.6% year-over-year to ...
    Cached Medicine Technology:Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 2Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 3Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 4China Sky One Medical Announces Third Quarter 2011 Results 2China Sky One Medical Announces Third Quarter 2011 Results 3China Sky One Medical Announces Third Quarter 2011 Results 4China Sky One Medical Announces Third Quarter 2011 Results 5China Sky One Medical Announces Third Quarter 2011 Results 6China Sky One Medical Announces Third Quarter 2011 Results 7China Sky One Medical Announces Third Quarter 2011 Results 8China Sky One Medical Announces Third Quarter 2011 Results 9China Sky One Medical Announces Third Quarter 2011 Results 10China Sky One Medical Announces Third Quarter 2011 Results 11China Sky One Medical Announces Third Quarter 2011 Results 12China Sky One Medical Announces Third Quarter 2011 Results 13China Sky One Medical Announces Third Quarter 2011 Results 14China Sky One Medical Announces Third Quarter 2011 Results 15China Sky One Medical Announces Third Quarter 2011 Results 16China Sky One Medical Announces Third Quarter 2011 Results 17China Sky One Medical Announces Third Quarter 2011 Results 18
    (Date:8/20/2014)... 2014 Inc. Magazine recently named ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ... as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, ... exposure as members of the Inc. 500|5000. , ...
    (Date:8/20/2014)... 2014 Ticketability.com has Theresa ... fair prices. The well-known medium has been thrilling many ... touring in 19 cities, with tickets becoming available August ... will visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, ... Hills and San Diego. The medium’s fans can obtain ...
    (Date:8/20/2014)... August 20, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers,restraints, challenges, opportunities, current market trends,and strategies impacting ... estimates and forecasts of the revenue and share ...
    (Date:8/20/2014)... 20, 2014 GBK, the luxury lifestyle gift ... Award Nominees and Presenters at the annual GBK Gift Lounge. ... 23rd in Beverly Hills from 11am – 6pm. GBK will ... by DJ Morgan Hildebrand. , As always, GBK will blend ... several charities at the lounge. GO Campaign is a grantmaking ...
    (Date:8/20/2014)... What to Do Now for UDI:, ... the Market, **FDAnews Webinar**, Sept. 11, 2014 — 1:30 ... Hospitals and other buyers of devices lose $5 billion ... systems. , Complying with the FDA’s deadlines is important, ... UDI as soon as possible. If devicemakers don’t, ...
    Breaking Medicine News(10 mins):Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 2Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 3Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 4
    ... study , , MONDAY, Dec. 29 (HealthDay News) -- A ... natural and processed foods accelerated the growth of lung ... study suggests that dietary regulation of inorganic phosphates may ... prevention," Myung-Haing Cho, lead author of a report in ...
    ... among those whose families don,t accept them , , MONDAY, ... families rejected them when they were younger are more ... use and suicide attempts, new research suggests. , The ... a child,s sexuality directly causes problems later in life. ...
    ... Indulgence in a high-fat diet can not only ... also can affect the balance of circadian rhythms ... have shown. , The biological clock regulates the ... metabolism, and disturbance of the clock can lead to ...
    ... 29 Second Harvest Heartland, the,Upper Midwest,s largest ... Feeding America, General Mills and NBC,s "The Biggest ... pound participating dieters,in Minnesota and western Wisconsin pledge ... donate 10 cents to Second Harvest Heartland -- ...
    ... Ricinus communis is considered one of the most potent ... and inflammation and can result in death. Most accidental ... beans whereby the toxin is released after the seed ... damage with symptoms and death due to multiorgan failure ...
    ... NSAIDs and acetaminophen, are commonly used for the relief ... The gastrointestinal side effects of NSAIDs are well documented ... for the gastrointestinal system. Acute effects of short-term, especially ... adequately. , A research article to be published on ...
    Cached Medicine News:Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Rejection of Gay Teens Linked to Later Troubles 2Health News:Rejection of Gay Teens Linked to Later Troubles 3Health News:Another reason to avoid high-fat diet -- it can disrupt our biological clock 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 2Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 3Health News:Second Harvest Heartland, Feeding America, General Mills, and 'The Biggest Loser' Team to Help Community Lose Weight and Raise Funds to Feed the Hungry 4Health News:Acute gastric injury due to high-dose analgesics? 2
    ... anterior cervical plate system is the lowest ... height includes an integrated lock mechanism, which ... bone screws. Surgeons appreciate the narrow width, ... dissection required. The system also offers easy ...
    ... been providing excellence in Ambulatory ECG ... of physicians in the diagnosis and ... conditions each year. State-of-the-art equipment and ... the highest standard of customer service ...
    ... incubator is an extremely compact and ... microplate up to 50C. ,Solo ... higher temperatures up to 65C. Solo ... cost and high performance for varied ...
    The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
    Medicine Products: